相似文献
1
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
Vaccine. 2007 May 16;25(20):4093-102. doi: 10.1016/j.vaccine.2007.02.038. Epub 2007 Feb 27.
2
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.
Vaccine. 2008 Sep 26;26(41):5246-54. doi: 10.1016/j.vaccine.2008.07.057. Epub 2008 Aug 8.
3
Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
J Virol. 2014 Mar;88(6):3058-66. doi: 10.1128/JVI.03035-13. Epub 2013 Dec 11.
4
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
mBio. 2020 Feb 25;11(1):e00039-20. doi: 10.1128/mBio.00039-20.
5
Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
Viruses. 2021 Jan 30;13(2):214. doi: 10.3390/v13020214.
6
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736. doi: 10.1371/journal.pntd.0003736. eCollection 2015 Apr.
7
Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
Vaccine. 2012 Feb 14;30(8):1445-52. doi: 10.1016/j.vaccine.2011.12.134. Epub 2012 Jan 9.
8
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
J Virol. 2005 Nov;79(22):13934-42. doi: 10.1128/JVI.79.22.13934-13942.2005.
9
Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2406. doi: 10.1371/journal.pntd.0002406. eCollection 2013.
10
A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
mBio. 2020 Mar 24;11(2):e00186-20. doi: 10.1128/mBio.00186-20.
引用本文的文献
1
Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.
Future Pharmacol. 2025 Jun;5(2). doi: 10.3390/futurepharmacol5020026. Epub 2025 May 31.
2
Infusion of neutralization into Lassa vaccine design.
Trends Immunol. 2025 Jul;46(7):512-524. doi: 10.1016/j.it.2025.05.006. Epub 2025 Jun 24.
3
Current perspectives on vaccines and therapeutics for Lassa Fever.
Virol J. 2024 Dec 19;21(1):320. doi: 10.1186/s12985-024-02585-7.
4
A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.
NPJ Vaccines. 2024 Nov 17;9(1):220. doi: 10.1038/s41541-024-01012-w.
5
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.
Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x.
6
Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.
NPJ Vaccines. 2024 Aug 9;9(1):143. doi: 10.1038/s41541-024-00930-z.
7
The Importance of Lassa Fever and Its Disease Management in West Africa.
Viruses. 2024 Feb 7;16(2):266. doi: 10.3390/v16020266.
8
Progress toward the development of Lassa vaccines.
Expert Rev Vaccines. 2024 Jan-Dec;23(1):5-7. doi: 10.1080/14760584.2023.2290683. Epub 2023 Dec 11.
9
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection.
Nat Commun. 2023 Sep 12;14(1):5603. doi: 10.1038/s41467-023-41376-6.
10
Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice.
Front Trop Dis. 2022;3. doi: 10.3389/fitd.2022.847598. Epub 2022 Mar 10.
本文引用的文献
1
Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses.
Virus Genes. 2007 Apr;34(2):169-76. doi: 10.1007/s11262-006-0050-3. Epub 2006 Dec 2.
2
Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
J Virol. 2006 Sep;80(17):8351-61. doi: 10.1128/JVI.00896-06.
3
Historical Lassa fever reports and 30-year clinical update.
Emerg Infect Dis. 2006 May;12(5):835-7. doi: 10.3201/eid1205.050052.
4
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.
Lancet. 2006 Apr 29;367(9520):1399-404. doi: 10.1016/S0140-6736(06)68546-2.
5
Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages.
Microbes Infect. 2006 Apr;8(5):1194-202. doi: 10.1016/j.micinf.2006.02.002. Epub 2006 Mar 20.
6
CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus.
J Immunol. 2006 Apr 15;176(8):4940-9. doi: 10.4049/jimmunol.176.8.4940.
7
Phylogeny and evolution of old world arenaviruses.
Virology. 2006 Jul 5;350(2):251-7. doi: 10.1016/j.virol.2006.01.026. Epub 2006 Feb 21.
8
Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology.
J Clin Invest. 2006 Feb;116(2):465-75. doi: 10.1172/JCI25608. Epub 2006 Jan 19.
9
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
Virology. 2006 Feb 20;345(2):299-304. doi: 10.1016/j.virol.2005.12.001. Epub 2006 Jan 18.
10
Very virulent infectious bursal disease virus: reduced pathogenicity in a rare natural segment-B-reassorted isolate.
J Gen Virol. 2006 Jan;87(Pt 1):209-216. doi: 10.1099/vir.0.81184-0.
Zotero 插件